Stallergenes Pharma

Stallergenes Greer is a global healthcare company specializing in the diagnosis and treatment of allergies through allergen immunotherapy (AIT). The company develops and commercializes sublingual (tablets and drops) and subcutaneous treatments designed to reprogram the immune system to tolerate specific allergens. Its flagship products include ORALAIR for grass pollen allergy, ACTAIR for dust mite allergy, and Palforzia for peanut allergy, which was acquired from Nestlé Health Science in 2023. Stallergenes Greer operates a vertically integrated model, covering the entire value chain from allergen production to clinical development and distribution. The company was formed by the 2015 merger of the French company Stallergenes and the American company Greer Laboratories and is currently a private entity owned by Waypoint GP Limited. With a presence in 19 countries and manufacturing facilities in both Europe and the United States, the company serves a global patient base suffering from respiratory and food allergies.